Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
MVA-BN-Filo
|
| gptkbp:age |
adults and children aged 1 year and older
|
| gptkbp:alsoKnownAs |
Ad26.ZEBOV
Zabdeno |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
J07BX07
|
| gptkbp:clinicalTrialPhase |
conducted in Africa and Europe
|
| gptkbp:contains |
genetic material encoding Ebola virus glycoprotein
|
| gptkbp:developedBy |
gptkb:Johnson_&_Johnson
gptkb:Janssen_Pharmaceuticals |
| gptkbp:dosingSchedule |
two-dose regimen
|
| gptkbp:firstDose |
Ad26.ZEBOV
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ebola vaccine (Ad26.ZEBOV)
|
| gptkbp:indication |
prevention of Ebola virus disease
|
| gptkbp:regulates |
conditional marketing authorization in EU
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:secondDose |
MVA-BN-Filo
|
| gptkbp:secondDoseInterval |
approximately 8 weeks after first dose
|
| gptkbp:sideEffect |
fever
fatigue headache muscle pain injection site pain |
| gptkbp:storage |
2°C to 8°C
|
| gptkbp:target |
Ebola virus (Zaire ebolavirus)
|
| gptkbp:technology |
recombinant, replication-incompetent adenovirus type 26 vector
|
| gptkbp:usedIn |
Ebola outbreak response
|
| gptkbp:WHOPrequalified |
yes
|
| gptkbp:bfsParent |
gptkb:adenovirus_serotype_26_(Ad26)
|
| gptkbp:bfsLayer |
6
|